# Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening

> **NCT01578850** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 491 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Etanercept
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01578850
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-07
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 491 (ACTUAL)
- **Last updated:** 2016-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01578850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01578850, "Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT01578850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*